PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2020Theranostics157 citationsOpen Access

Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

View Full Paper
MYMadhav Prasad YadavAll India Institute of Medical SciencesSBSanjana BallalAll India Institute of Medical SciencesRSRanjit Kumar SahooNational Institute of Technology Rourkela

Key Points

Key points are not available for this paper at this time.

Abstract

Ac-PSMA-617 TAT showed promising disease control rate, even when all other therapeutic options were exhausted, with low treatment-related toxicities.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yadav et al. (2020) studied this question.

synapsesocial.com/papers/6a02548ddc09a3db38b364b2https://doi.org/10.7150/thno.48107
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience2019 · 217 citations
  2. 2225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study2018 · 354 citations
  3. 3From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors2009 · 3,817 citations
  4. 4Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer2015 · 612 citations
  5. 5The Use of the Karnofsky Performance Scale in Determining Outcomes and Risk in Geriatric Outpatients1991 · 343 citations